TRX-818 - CAS# 1256037-58-7 039 Smiles: CC1=C(C2=CC=C(O)C=C2N1C1C=CC(=CC=1)OC)[N+]([O-])=O

Smiles: CC1=C(C2=CC=C(O)C=C2N1C1C=CC(=CC=1)OC)[N+]([O-])=O

36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10

5 nM in cells exogenously expressing human Mps1

Regulation of circadian behavior and metabolism by REV-ERB-α and REV-ERB-β

LLY-507 was used at 10 µM final concentration in various in vitro assays

TRX-818 - CAS# 1256037-58-7 039 Smiles: CC1=C(C2=CC=C(O)C=C2N1C1C=CC(=CC=1)OC)[N+]([O-])=OTRX 818, also known as Foslinanib, CVM 1118, CAS No. 1256037 58 7, is an orally bioavailable agent with potential antineoplastic and anti vasculogenic mimicry (VM) activities. Although the exact multiple mechanisms of action through which this agent exerts its effects have yet to be fully elucidated, TRX 818, upon oral administration appears to induce cancer cell apoptosis and inhibits cancer cell proliferation. This agent also prevents tumor cell VM